Truxima
Provider 
Founded —
Sells To —
Pricing Model —
Ownership —

Truxima is a rituximab biosimilar medicine used in blood cancer and autoimmune care.
Truxima is a prescription rituximab biosimilar used to treat adults with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It is also approved for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris.
The medicine is delivered as an intravenous infusion with full prescribing information and boxed warnings. In the United States, product support and adverse event reporting are handled through Teva.
Bionovis

Bionovis — Biologic and Biosimilar Medicines
bionovis.com.br
Libbs Farmaceutica

Hematológicos
libbs.com.br
| Attribute | Truxima | Bionovis — Biologic and Biosimilar Medicines | Hematológicos | |
|---|---|---|---|---|
| Provider | ||||
| Founded | — | 2012 | 1958 | |
| Sells To | — | — | Consumers, Enterprise | |
| Pricing Model | — | — | Recurring, Software | |
| Ownership | — | — | Private |
Provider 
Founded —
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 2012
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 1958
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Private




Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.


Biocon's biosimilars portfolio spans trastuzumab, bevacizumab, pegfilgrastim, adalimumab, etanercept, and aflibercept products.
Samsung Bioepis's biosimilars portfolio includes etanercept, adalimumab, infliximab, trastuzumab, and aflibercept products.


Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.


Biopharma business unit of Fresenius Kabi Brasil offering biosimilar medicines in Brazil.
Ruxience is Pfizer's rituximab-pvvr biosimilar medicine for blood cancers.

Riabni is Amgen's rituximab-arrx biosimilar for blood cancers.
Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.

Biocon's biosimilars portfolio spans trastuzumab, bevacizumab, pegfilgrastim, adalimumab, etanercept, and aflibercept products.

Samsung Bioepis's biosimilars portfolio includes etanercept, adalimumab, infliximab, trastuzumab, and aflibercept products.
Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.

Biopharma business unit of Fresenius Kabi Brasil offering biosimilar medicines in Brazil.
